Using NAFLD steatosis signatures from a published mouse study (Chella Krishnan et al., 2018) and the CTD NAFLD signatures (Davis et al., 2017), we predicted PPAR alpha agonists (clofibrate, fenofibrate, bezafibrate, and gemfibrozil), HMG-CoA reductase inhibitors (lovastatin, fluvastatin, and simvastatin), a PPAR gamma agonist (rosiglitazone), and a nonsteroidal anti-inflammatory drug (aspirin) to be among the top 10% of drug candidates based on the average ranking of drugs predicted using both the mouse steatosis signature and CTD NAFLD signature (Table S4). Here, PPARG is linked to steatosis.